Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 12:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1993–2016 of 196,718 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: ALL Clear all

Conditions: Diabetes Mellitus, Type 2
Interventions: New use of semaglutide injection, New initiation of "standard of care" (SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral); Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 2,316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Exocrine Pancreatic Insufficiency
Interventions: RELiZORB, Placebo; Device
Lead sponsor: Alcresta Therapeutics, Inc.; Industry
Eligibility: 4 Years to 45 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 11
States / cities: Los Angeles, California • Boise, Idaho • Indianapolis, Indiana + 8 more

Conditions: Pain, Postoperative
Interventions: Ketolorac; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 90 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Beachwood, Ohio

Conditions: Depressive Disorder, Major, Suicidal
Interventions: SLS-002, Placebo, Standard of care, Intranasal device; Drug · Other · Device
Lead sponsor: Seelos Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 21
States / cities: Orange, California • Panorama City, California • San Diego, California + 18 more

Conditions: Atherosclerosis
Interventions: Darapladib, Diltiazem; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Influenza
Interventions: 2 0.5 ml doses of '04-05 Trivalent Influenza Vaccine; Biological
Lead sponsor: Kaiser Permanente; Other
Eligibility: 5 Years to 8 Years
Enrollment: 280 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Dementia, Alzheimer Disease
Interventions: Skill Training Condition - problem solving training, REACH for TLC (Telephone Linked Computer) system; Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 21 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2001
U.S. locations: 5
States / cities: Birmingham, Alabama • Menlo Park, California • Miami, Florida + 2 more

Conditions: Herpes Simplex Virus
Interventions: Novel Antiviral Drug, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 1 Day to 98 Days
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 18
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 15 more

Conditions: Immune System Disorder, Healthy Volunteers
Interventions: Belumosudil, UGT1A1 victim drug, P-gp victim drug, OATP1B1/BCRP victim drug; Drug
Lead sponsor: Kadmon, a Sanofi Company; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Infantile Spasm
Interventions: Fenfluramine; Drug
Lead sponsor: Children's Hospital of Orange County; Other
Eligibility: 12 Months to 36 Months
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Los Angeles, California • Orange, California

Conditions: Major Depressive Disorder
Interventions: 5-hydroxytryptophan and Creatine monohydrate; Drug
Lead sponsor: Perry Renshaw; Other
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Pompe Disease
Interventions: Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase, Rapamycin, saline, Rituxan, Diphenhydramine, Acetaminophen, Lidocaine, LMX 4 Topical Cream; Genetic · Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 50 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Mindfulness, Meditation, Metastatic Cancer, Quality of Life, Advance Care Planning, Palliative Care, Family Caregiver, Supportive Care
Interventions: Mindfulness; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Autism Spectrum Disorder
Interventions: Sibling-mediated intervention; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 5 Years to 11 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Round Rock, Texas

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Aclidinium bromide/formoterol Fixed-Dose Combination (FDC), Aclidinium bromide, Formoterol Fumarate, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 921 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 179
States / cities: Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 146 more

Conditions: Ventral/Incisional Hernia Repairs
Interventions: Not listed
Lead sponsor: University of Kentucky; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Advanced Solid Tumors, NSCLC Adenocarcinoma, Cholangiocarcinoma, Pancreatic Carcinoma, Colorectal Carcinoma
Interventions: MGC028; Biological
Lead sponsor: MacroGenics; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 7
States / cities: San Francisco, California • Boston, Massachusetts • Grand Rapids, Michigan + 3 more

Conditions: ANXIETY DISORDERS (or Anxiety and Phobic Neuroses)
Interventions: CERC-501, placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 6
States / cities: New Haven, Connecticut • Indianapolis, Indiana • New York, New York + 3 more

Conditions: Diabetes Mellitus, Type 2
Interventions: GSK716155 subcutaneous injections, placebo injection; Drug · Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 5
States / cities: Miramar, Florida • Orlando, Florida • Honolulu, Hawaii + 2 more

Conditions: Colon Cancer, Rectal Cancer
Interventions: AlloMEM™; Biological
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Pre-Exposure Prophylaxis
Interventions: Probenecid Oral Tablet, Tenofovir disoproxil fumarate/Emtricitabine; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Bi-polar II Disorder
Interventions: Active CES, Sham CES; Device
Lead sponsor: Beth Israel Medical Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Epithelium, Corneal
Interventions: Moxifloxacin, Gatifloxacin; Drug
Lead sponsor: Walter Reed Army Medical Center; Federal
Eligibility: 21 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2005
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Cardiovascular Diseases, Obesity
Interventions: Wait-List Control, PREVENT Tool; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 64 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

Prediction of the SEPRA Diabetes Trial in Healthcare Claims Data

Safety, Tolerability and Fat Absorption Using Enteral Feeding In-line Enzyme Cartridge (Relizorb)

Ketolorac Versus Saline at Laparoscopic Incision Sites

A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide

Study to Determine the Effect of Repeated Administration of Diltiazem on the Pharmacokinetics of Darapladib (Sb-480848).

A Comparison of One Versus Two Doses of Influenza Vaccine in Children 5-8 Years of Age

Coordinating Center for Enhancing ADRD Caregiving

A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)

A Study to Assess the Effect of Oral Belumosudil on Inhibition of Various Proteins in the Fed State in Healthy Male Subjects

Treatment of Refractory Infantile Spasms With Fenfluramine

5-hydroxytryptophan and Creatine for Treatment Resistant Depression Associated With Hypoxia in Females

Re-administration of Intramuscular AAV9 in Patients With Late-Onset Pompe Disease

Mindfulness to Enhance Quality of Life and Support Advance Care Planning

Sibling-Mediated Intervention on Literacy and Reciprocity for Children With Autism

Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)

Trunk Strength Study

A Study of MGC028 in Participants With Advanced Solid Tumors

Fast-Fail Trials in Mood and Anxiety Spectrum Disorders; Kappa Opioid Receptor Phase 2a

In-patient Study With GSK716155 In Patients With Type 2 Diabetes Mellitus

Pilot Study Evaluating the Efficacy of AlloMEM After Loop Ileostomy

Assessment of a New "Boosting" Strategy for HIV Pre-exposure Prophylaxis in Healthy Volunteers

A Single Blind Study of Cranial Electrical Stimulation in Bipolar II Disorder

Comparison of the Effect of 4th Generation Fluoroquinolones, Gatifloxacin and Moxifloxacin, on Epithelial Healing Following Photorefractive Keratectomy (PRK), A Substudy of: Initial Evaluation of Excimer Laser Keratorefractive Surgery in U.S. Army Personnel (WU # 2335-99)

Evaluation of a Novel Technology to Support Tailored Health Behavior Counseling in Rural Primary Care Clinics